DSM HAS mov to fill a gap in its biopharmaceutical activities on establishing an alliance with Crucell NV a Dutch biotechnology company specializing in technology platforms for therapeutic proteins.

DSM HAS mov to fill a gap in its biopharmaceutical activities on establishing an alliance with Crucell NV a Dutch biotechnology company specializing in technology platforms for therapeutic proteins.
by means of its 60 percent owned subsidiary DSM Biologics, DSM is building 60000 liters of fermentation capacity in Montreal, Canada, for large-scale production of monoclonal antibodies and recombinant proteins based forward mammalian cell culture.
on the other hand DSM acknowledges that it wants greater technological expertise in the disentanglement of cell lines for the contract manufacturing of

...